Get to know our clinical trials

Clinical trial of navitoclax in monotherapy and in combination with ruxolitinib in patients with myeloproliferative neoplasms.

THE PURPOSE OF THIS STUDY IS TO UNDERSTAND THE EFFECTS THAT NAVITOCLAX MAY HAVE ON YOUR HEART, SPECIFICALLY, ON ELECTROCARDIOGRAPHIC MEASUREMENTS IN PATIENTS WITH MYELOFIBROSIS OR CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE U.S. AND EUROPE.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 1 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF NAVITOCLAX IN MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
  • Code EudraCT: 2020-002597-27
  • Protocol number: M19-753
  • Promoter: Abbvie farmacéutica
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.